Caris Life Sciences vs CorVel
CorVel reported revenue of $958 million in fiscal 2026, 1.2 times Caris Life Sciences' $812 million in fiscal 2025. Caris Life Sciences' revenue grew 97.0% in its latest year, and CorVel's grew 7.0%. Free cash flow was $67 million at Caris Life Sciences and $110 million at CorVel. Their fiscal years end in different months (December 31 and March 31), so the periods don't line up exactly.
Side by side
| Caris Life Sciences | CorVel | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Mar 31, 2026 |
| Revenue | $812M | $958M |
| Revenue growth | 97.0% | 7.0% |
| Revenue growth a year, last 5 years | — | 11.6% |
| Gross margin | — | 24.3% |
| Operating margin | 5.6% | — |
| Net margin | −8.4% | 11.5% |
| Free cash flow | $67M | $110M |
| Free cash flow margin | 8.2% | 11.5% |
| Return on capital | — | — |
| Net debt to EBITDA | −6.2x | — |
| Dividends and buybacks | $0M | $56M |
| Change in diluted share count | 371.0% | −0.7% |
| Last close | $18.54 | $87.36 |
| P/E at the last close | — | 36.7× |
| Insider trades, last 12 months | bought $1.5 million, sold $28.9 million | sold $22.5 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Caris Life SciencesCorVel
Operating margin
Percent of revenue
Caris Life SciencesCorVel
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Caris Life SciencesCorVel
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Caris Life Sciences and CorVel pages.